OncoMatch/Clinical Trials/NCT06438822
Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
Is NCT06438822 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for cholangiocarcinoma.
Treatment: Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil — This study aimed to evaluate the efficacy and safety of the combination of cadonilimab with liposomal irinotecan plus fluorouracil and leucovorin for the treatment of advanced biliary tract cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: gemcitabine-based systemic chemotherapy (gemcitabine)
Progression after prior gemcitabine-based systemic chemotherapy and refused or were intolerable to initial treatment with gemcitabine-based chemotherapy regimens
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5*10^9/L , platelet count ≥75*10^9/L , hemoglobin ≥90g/L
Kidney function
serum creatinine ≤1.5 × upper limit of normal
Liver function
Alanine aminotransferase, and aspartate aminotransferase ≤2.5 × upper limit of normal; Total bilirubin ≤1.5 × upper limit of normal
Adequate organ and bone marrow function as below: Absolute neutrophil count ≥1.5*10^9/L , platelet count ≥75*10^9/L , hemoglobin ≥90g/L; Alanine aminotransferase, and aspartate aminotransferase ≤2.5 × upper limit of normal; Total bilirubin and serum creatinine ≤1.5 × upper limit of normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify